Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial

Published:2015-11 Issue:15 Volume:16 Page:1525-1536
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Rambaldi Alessandro,Grassi Anna,Masciulli Arianna,Boschini Cristina,Micò Maria Caterina,Busca Alessandro,Bruno Benedetto,Cavattoni Irene,Santarone Stella,Raimondi Roberto,Montanari Mauro,Milone Giuseppe,Chiusolo Patrizia,Pastore Domenico,Guidi Stefano,Patriarca Francesca,Risitano Antonio M,Saporiti Giorgia,Pini Massimo,Terruzzi Elisabetta,Arcese William,Marotta Giuseppe,Carella Angelo Michele,Nagler Arnon,Russo Domenico,Corradini Paolo,Alessandrino Emilio Paolo,Torelli Giovanni Fernando,Scimè Rosanna,Mordini Nicola,Oldani Elena,Marfisi Rosa Maria,Bacigalupo Andrea,Bosi Alberto

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials;Koreth;JAMA,2009

2. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach;Cornelissen;Nat Rev Clin Oncol,2012

3. Shouval R, Labopin M, Unger R, et al. Prediction of allogeneic HSCT related mortality in acute leukemia: exploring boundaries of prediction through machine learning based modeling: a data mining study from the Acute Leukemia Working Party (ALWP) of the EBMT. 56th ASH Annual Meeting and Exposition; San Francisco, CA; Dec 6–9, 2014. Abstract 2568.

4. Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia in Remission: Comparison of Intravenous Busulfan Plus Cyclophosphamide (Cy) Versus Total-Body Irradiation Plus Cy As Conditioning Regimen—A Report From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

5. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation;Bredeson;Blood,2013

Cited by 149 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Addition of ruxolitinib and decitabine to modified busulfan/cyclophosphamide conditioning regimen for prophylaxis relapse in high-risk acute myeloid leukemia: the phase 2 prospective study;Annals of Hematology;2024-09-07

2. Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial;Blood Cancer Journal;2024-08-21

3. How to Run a Successful Transplant Program in Older Patients with Myeloid Malignancies;Transplantation and Cellular Therapy;2024-08

4. Busulfan-Fludarabine Versus Busulfan-Cyclophosphamide for Allogeneic Transplant in Acute Myeloid Leukemia: Long Term Analysis of GITMO AML-R2 Trial;2024-07-18

5. A network meta-analysis of the effectiveness of different basic preconditioning regiments in allogeneic hematopoietic stem cell transplantation;Hematology;2024-07-15